Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AVEO, Astellas Say Tivozanib Superior To Sorafenib In Advanced RCC - Quick Facts

AVEO Pharmaceuticals, Inc. (AVEO: Quote) and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Tuesday said that tivozanib Phase 3 clinical trial demonstrated superiority over sorafenib in the primary endpoint of progression-free survival in patients with advanced renal cell carcinoma.

TIVO-1, a global, randomized Phase 3 clinical trial evaluated the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma. TIVO-1 is the first registration study in first-line renal cell carcinoma that is comparing an investigational agent against an approved VEGF therapy.

The companies noted that tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors

Based on these data, AVEO and Astellas currently plan to submit for marketing approval of tivozanib in the US and Europe in 2012.

Click here to receive FREE breaking news email alerts for AVEO Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following the lackluster performance seen during the previous session, stocks may move to the downside in early trading on Tuesday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 33 points. Germany's investor confidence weakened to a level last seen in late 2012 amid concerns that the rising geopolitical tensions are hurting the European economy, data from the Centre for European Economic Research/ZEW showed Tuesday. The ZEW economic sentiment index fell to 6.9 in September from 8.6 in August. The index has been falling since last January and matched the score seen in December 2012. U.K. inflation slowed marginally as expected in August on falls in prices of motor fuels and food, data from the Office for National Statistics revealed Tuesday. Factory-gate prices declined for the second straight month indicating benign inflationary pressures in the pipeline. Consumer prices rose 1.5 percent year-on-year in August, slower than the 1.6 percent rise in July.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.